Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Gabriella McCarty

NP-C

Gabriella McCarty is a gastroenterology/hepatology nurse practitioner. She obtained her masters and nurse practitioner degree at Case Western Reserve University in 2004. She has been practicing in this field for 26 years. She serves as faculty for Gastroenterology/ Hepatology Advanced Practice Providers (GHAPP) and is an American College of Gastroenterology (ACG) committee member, serving on the education subcommittee. She will be completing her doctorate of nursing in May 2025. She loves all aspects of GI / Hepatology, education and nursing.

play

Alison Moe

PA-C

Alison S. Moe, MS, PA-C, is a board-certified physician assistant specializing in gastroenterology at United Digestive's Braselton office in Hoschton, Georgia. She earned her Master of Science in Medical Education from Seton Hall University and a Bachelor of Arts in Physical Anthropology from the State University of New York at Stony Brook. Alison is fluent in Spanish and has a special interest in treating irritable bowel syndrome and liver disease. With almost two decades of experience as a Physician Assistant, Alison has developed a strong foundation in both clinical practice and research, particularly in the fields of gastroenterology and hepatology. Alison's dedication to patient care includes extensive clinical hours, allowing her to cultivate deep relationships with patients as well as national experts caring for individuals, especially those suffering from inflammatory bowel disease (IBD) and advanced liver disease. Alison's commitment to advancing the understanding and treatment of these conditions drives my clinical practice and ongoing research efforts, aiming to provide the highest standard of care for my patients.

play

Christie Morrison

AGACNP-BC

Christie Morrison is a Board Certified Adult Advanced Practice Nurse and Lead APP at Oshi Health, a digital digestive health practice and IBD APP at Texas Digestive Disease Consultants in San Antonio, Texas. She strives to improve the lives of patients with chronic gastrointestinal conditions through a multidisciplinary approach. She has worked in various roles as a GI advanced practice provider, including inpatient, outpatient clinic, and telehealth since 2015. Mrs. Morrison is currently an active member of the American College of Gastroenterology where she is serving on the Editorial Board. She is also a member of several GI societies, including TSGE, AGA, ASGE, and GHAPP. Christie was recently honored with the ACG APP Clinical Excellence Award for community practice. She collaborates with industry partners and GI colleagues to enhance education and engagement for APPs working in Gastroenterology. She strives to improve the quality of life and better patient outcomes in all chronic GI conditions and believes that providing resources to her peers through education can help her achieve this goal.

MASLD/MASH Learning Center

Latest News & Blogs

Oral delivery of chitosan-bilirubin nanoparticles alleviates hepatic inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis

July 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a severe chronic liver disease that often leads to complications, such as cirrhosis and hepatocellular carcinoma. Despite intensive research and development efforts, there are relatively few approved therapeutics for MASH. Here, we report an oral nanomedicine comprising bilirubin-conjugated low molecular weight water-soluble chitosan (designated LMWC-BRNPs) that can alleviate oxidative stress and lipogenesis in liver to treat MASH in a...

Read More arrow

Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study

July 2025

CONCLUSION: Chiglitazar significantly reduced liver fat content in MASLD with hypertriglyceridemia and insulin resistance, with a dose-dependent effect and favorable safety profile.

Read More arrow

E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p

July 2025

CONCLUSIONS: E2F2 deficiency protects against MASH and cholestasis preventing cholesterol accumulation, fibrosis, and inflammation through modulation of miR-34a-5p, which could provide therapeutic benefits for patients with cholestatic-MASH.

Read More arrow

"Weekend Warrior" Exercise Pattern Protects Against MASLD and Mortality Comparable to Regular Exercise: National Cohort Study

July 2025

CONCLUSIONS: WW physical activity patterns protect from MASLD and all-cause mortality comparable to regular exercise.

Read More arrow

Cardiovascular implications of MASLD: overview of the evidence

July 2025

CONCLUSION: MASLD seems to be an independent cardiovascular risk factor, but further studies are warranted to clarify the distinct impacts of MASLD stages and their interplay with MS on cardiovascular outcomes.

Read More arrow

The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease

July 2025

The prevalence of type 2 diabetes mellitus (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly increasing worldwide. MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is defined as a condition of steatotic liver disease (SLD) with one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake. The variety of MASLD includes steatosis, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), fibrosis,...

Read More arrow

Bupleuri Radix polysaccharides enhance the efficacy and intestinal absorption of baicalin via regulating intestinal beta-glucuronidase activity in MASH mice

July 2025

CONCLUSION: BRP improved BAI's intestinal absorption and therapeutic efficacy in MASH mice, potentially by modulating gut microbiota and enhancing β-GUS activity, thereby facilitating the deglycosylation of BAI. These findings reveal the potential synergistic mechanism of Bupleuri Radix-Scutellariae Radix pair and propose a feasible approach to improve the bioavailability and therapeutic effect of BAI.

Read More arrow

Red blood cell-derived extracellular vesicles deliver NUP85 siRNA to alleviate MASLD through downregulating SLC27A1/PPAR-γ in hepatocyte

July 2025

Hepatic steatosis and inflammation, resulting from excessive hepatic lipid deposition, are hallmarks of metabolic dysfunction-associated fatty liver disease (MASLD). Recent studies have indicated that nucleoporin 85 (NUP85) influences lipid metabolism in liver cells; however, the role of NUP85 in the diagnosis and treatment of MASLD remains unclear. Firstly, results showed that compared to healthy controls, serum levels of NUP85 were elevated in patients with metabolic dysfunction-associated...

Read More arrow

Peroxisome Proliferator-activated Receptor Agonist IVA337 Alleviates Inflammation and Fibrosis in MASH by Restoring Lipid Homeostasis

July 2025

Metabolic dysfunction-associated steatohepatitis (MASH), an advanced stage of metabolic dysfunction-associated steatotic liver disease (MASLD), is characterized by significant hepatic fibrosis and inflammation. The pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist IVA337 (lanifibranor) has demonstrated potential as an anti-MASH therapeutic, although its mechanisms of action remain incompletely understood. This study explores the effects and mechanisms of IVA337 using two distinct...

Read More arrow

Chemoprevention for hepatocellular carcinoma using GalNAc-siRNAs

July 2025

The ability to prevent hepatocellular carcinoma (HCC) in patients with chronic liver disease remains an unmet clinical need. We performed a head-to-head comparison of GalNAc-conjugated siRNA mediated inhibition of five genes (CDK1, PD-L1, CTNNB1, SMYD3, ANLN) for cancer prevention in four distinct autochthonous HCC mouse models. siCdk1 and siAnln increased overall survival in the CTNNB1/MYC hydrodynamic transfection model, where HCC formation is driven by oncogenes. Both long-term and transient...

Read More arrow

Myeloid TGF-beta signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis

July 2025

CONCLUSIONS: These findings identify myeloid TGF-β signaling as a key driver of liver macrophage heterogeneity and polarization within the microenvironment during the progression of MASH and MASH-associated liver cancer.

Read More arrow

Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review

July 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly recognized as a leading cause of hepatocellular carcinoma (HCC), the third-leading cause of cancer mortality worldwide, driven by the global obesity epidemic. Projected to become the primary cause of HCC by 2030, MASH-HCC presents unique clinical challenges. This review examines its clinical management, including surveillance strategies and treatment advances, and discusses prospects to overcome existing challenges. MASH-HCC...

Read More arrow

EDIL3 Deficiency Attenuates Liver Fibrosis Through Inhibiting Hepatic Stellate Cells Activation via the Integrin alphavbeta3-ERK1/2-RUNX2 Axis in MASH Mice

July 2025

Metabolic Dysfunction-Associated Steatohepatitis (MASH) emerges as an advanced stage of Metabolic Dysfunction-Associated Steatotic Liver Disease, marked by significant liver damage characterized by fat accumulation, inflammation, hepatocyte injury, and progressive fibrosis. Epidermal Growth Factor-like repeat and Discoidin I-like domain-containing protein 3 (EDIL3), a protein containing epidermal growth factor-like repeats and discoidin I-like domains, interacts with membrane integrins to...

Read More arrow

A comparison of the predictive value of 12 body composition markers for MASLD, at-risk MASH and increased liver stiffness in a general population setting

July 2025

CONCLUSION: In the general population, MASLD and MASH risk increased even when WC < 100 cm, while increased LSM risk was increasing only >100 cm. Although relatively minor differences, WC consistently demonstrated the highest predictive value for MASLD, at-risk MASH, and increased LSM and therefore most suited for MASLD diagnosis, management and risk stratification.

Read More arrow

Non-hematopoietic roles of erythropoietin in inflammation and metabolic disorders

July 2025

Erythropoietin (EPO), a glycoprotein hormone primarily produced by the kidneys, is essential for erythropoiesis. Beyond its well-established hematopoietic function, EPO has emerged as a regulator of metabolic inflammation. Obesity-induced chronic inflammation underlies insulin resistance, a key driver of metabolic disorders such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH). Recent evidence shows EPO exerts anti-inflammatory effects in...

Read More arrow

Hepatocyte FoxO1 depletion exacerbates hepatic inflammation in MASH by targeting cystathionine gamma-lyase

July 2025

The transcription factor Forkhead box protein O1 (FoxO1) is a well-established regulator of glucose and lipid metabolism, yet its role in metabolic dysfunction-associated steatohepatitis (MASH) pathogenesis remains debated. This study investigates hepatocyte-specific FoxO1 mechanisms driving hepatic inflammation in MASH. Using hepatocyte-specific FoxO1-knockout (KO) mice fed a methionine-choline-deficient diet and LPS-treated FoxO1-KO cells, we demonstrated that FoxO1 depletion exacerbates...

Read More arrow

Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?

July 2025

Metabolic dysfunction-associated steatohepatitis with significant fibrosis is the aggressive form of steatotic liver disease that can progress to cirrhosis and its complications. Resmetirom is a liver-directed thyroid hormone receptor beta agonist that recently received accelerated approval by the FDA based on the results of the MAESTRO trial that demonstrated reasonable safety and efficacy in achieving both MASH resolution and fibrosis regression based on histological assessment. In this...

Read More arrow

Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide

July 2025

CONCLUSION: These post hoc analyses suggest that tirzepatide was consistently associated with improved MASH resolution without worsening of fibrosis across subgroups defined by demographics, histology, and biomarkers, compared with placebo.

Read More arrow

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

July 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than a quarter of the adult population worldwide. MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), which is associated with increased risk of progression to liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as cardiovascular complications. The pathogenesis of MASLD is complex and initiated by altered metabolic signalling circuits between the adipose tissue, muscle, gut and...

Read More arrow

A Real-World Experience With Resmetirom: Tolerability and Access

July 2025

CONCLUSION: Resmetirom is a safe medication with good tolerability in regard to the side effect profile for the first 3 months. Most patients were able to gain insurance approval but delays in dispensing and insurance requirements of invasive fibrosis testing to obtain approval were observed.

Read More arrow